I think there are two more factors worth touching on that make things difficult in drug discovery:
1. It feels like you're differentiating a bit but I always hear of the APIs being leaky. The selection of a target in the target discovery phase may drive which modalities are even available to try to engineer an intervention (e.g., intracellular vs extracellular targets can be addressed with different types of drugs). Clinical factors can also determine whether a particular modality is appropriate (e.g., keeping drugs refrigerated).
2. Costs create constraints that need to be applied at all the stages of the pipeline. Does gathering evidence during target discovery require a unique assay or access to very rare patient samples? What is the size of the addressable market? If you can only target a narrow patient population, it may not end up justifying the costs involved in running the clinical trials. If your chosen drug modality costs $500k to synthesize one dose, how will it be paid for?
I'm a big fan of Tiller [1], which is a paid service that basically just connects Yodlee to Google Docs or Excel. It will dump all your transactions and balance info into a spreadsheet and you can do what you want with it. It also has lots of templates for things like budgeting etc. I run a daily cron job that loads the transaction data and produces a nice Jupyter-based report. It will require some custom building, but the API plumbing is done for you.
One thing I miss from Google is relatively seamless integration with maps. Sometimes the address queries just fail for me on Kagi. And even when they don’t, Google’s maps are still far more useful IMO.
How does this compare with Concertmaster? It's basically a skin on top of Spotify for browsing classical music. It's free and pretty good. (There's also an app.) And I believe there is a version for Apple Music already?
Patch Bio | Computational Biologist | New York City | Full-time | REMOTE
Patch Bio engineers DNA for gene therapy. We build technology to make gene therapies safer and more effective, and able to address a broader range of diseases. To do that, we work at the interface of genomics, machine learning, and DNA synthesis. We are a seed-stage, venture-backed biotech startup based in New York City.
We're looking for a Computational Biologist who will be the connective tissue between the wet and dry lab. You will design DNA libraries, analyze sequencing data, and build predictive models of genetic regulation.
Alchemab Therapeutics | London, Cambridge UK | Software/Data Engineer | ONSITE, VISA | Full-time
Alchemab Therapeutics is a VC-backed newco that is bringing together the latest advances in antibody repertoire profiling, deep learning, and synthetic DNA libraries to discover new antibody-based drugs in a variety of disease areas including oncology and neuroscience. Alchemab aims to deliver a pipeline of targets and therapeutic candidates over the next 18 months.
We are looking for a data engineer with cloud expertise to help build and maintain our cloud/software infrastructure. This person will work closely with our bioinformatics/statistics experts to build reliable data processing pipelines and define/implement software engineering/devops best practices.
Experience with at least some of the following is a requirement:
- AWS stack, including administration and various database products
- Data storage, (relational) data modeling, workflow engines and schedulers
- Python data stack
- Distributed computing engines, such as Spark or Dask
- Docker containerization
Experience with bioinformatics, next-generation DNA sequencing (NGS), and genomics pipelines is a plus.
The ideal candidate will feel comfortable taking the lead at a small startup to define and implement devops and data engineering tasks.
Alchemab Therapeutics | London, Cambridge UK | Software/Data Engineer | ONSITE, VISA | Full-time
Alchemab Therapeutics is a VC-backed newco that is bringing together the latest advances in antibody repertoire profiling, deep learning, and synthetic DNA libraries to discover new antibody-based drugs in a variety of disease areas including oncology and neuroscience. Alchemab aims to deliver a pipeline of targets and therapeutic candidates over the next 18 months.
We are looking for a data engineer with cloud expertise to help build and maintain our cloud/software infrastructure. This person will work closely with our bioinformatics/statistics experts to build reliable data processing pipelines and define/implement software engineering/devops best practices.
Experience with at least some of the following resources is a plus:
- AWS stack, including administration and various database products
- Data storage, (relational) data modeling, workflow engines and schedulers
- Python data stack
- Distributed computing engines, such as Spark or Dask
- Docker containerization
The ideal candidate will feel comfortable taking the lead at a small startup to define and implement devops and data engineering tasks.
If you're interested, send an email to Olivia, our head of operations: [email protected].
I think there are two more factors worth touching on that make things difficult in drug discovery:
1. It feels like you're differentiating a bit but I always hear of the APIs being leaky. The selection of a target in the target discovery phase may drive which modalities are even available to try to engineer an intervention (e.g., intracellular vs extracellular targets can be addressed with different types of drugs). Clinical factors can also determine whether a particular modality is appropriate (e.g., keeping drugs refrigerated).
2. Costs create constraints that need to be applied at all the stages of the pipeline. Does gathering evidence during target discovery require a unique assay or access to very rare patient samples? What is the size of the addressable market? If you can only target a narrow patient population, it may not end up justifying the costs involved in running the clinical trials. If your chosen drug modality costs $500k to synthesize one dose, how will it be paid for?